Onco-Innovations Advances PNKP Inhibitor ONC010 as Emerging DDR Therapy

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) is advancing its lead candidate ONC010, a nanoparticle-encapsulated PNKP inhibitor designed to disrupt DNA repair pathways exploited by cancer cells. The company is positioning itself as a leader in the emerging PNKP inhibitor class, a subset of the broader DNA Damage Response (DDR) therapy market that differs from established PARP inhibitor therapies.

The company holds five patents protecting its PNKP inhibitor technology, nanoparticle delivery platform and related applications, which strengthens its intellectual property position as development progresses. Through its wholly owned subsidiary Inka Health, Onco-Innovations has integrated the SynoGraph causal AI platform to support patient stratification, clinical trial design and oncology evidence generation.

Ongoing CMC, IND-enabling and preclinical development activities are intended to support advancement of ONC010 toward planned first-in-human clinical studies. The company's dual-platform approach combines proprietary drug development with AI-enabled technologies to support oncology research, clinical development, patient stratification and evidence generation.

The company's strategy is centered on building a scalable oncology platform supported by proprietary intellectual property, strategic collaborations and integrated development capabilities. In recent years, Onco-Innovations has expanded its operational footprint through acquisitions and research partnerships.

Onco-Innovations is a clinical-stage oncology company focused on advancing a new class of DDR therapies and developing artificial intelligence-driven precision oncology solutions. The company is leading the development of PNKP inhibitors, an emerging category of DDR therapeutics targeting DNA repair pathways involved in cancer survival and resistance.

For the latest news and updates relating to ONNVF, visit the company's newsroom at https://ibn.fm/ONNVF.